Multiple myeloma (MM) therapy is evolving, and several new drugs are now available, extending patients’ life and exposure to different compounds and toxicities. We conducted a cross-sectional observational study enrolling 93 consecutive patients on active treatment for MM, aiming to assess their ocular complications. All the patients underwent a comprehensive ophthalmic evaluation. In our cohort, prevalence of low visual acuity was in line with similar age healthy population reported in registry studies. Interestingly, we recorded a higher prevalence of lens opacities (46%) and dry eye syndrome (53%). Nevertheless, we did not find any significant association between ocular disorders and anti-myeloma treatments, even steroid therapy. This observation suggests that other factors besides treatments, such as M-protein deposition in eye structures, may have a role in developing ocular toxicities. Since MM patients are elderly patients at higher risk of age-related eye disorders, we recommend periodic ophthalmic assessment in daily practice.
Ocular disorders in multiple myeloma patients: cross-sectional study of prevalence and association with treatment / M. Pennisi, L. Berchicci, E. Miserocchi, A. Mussetti, V. Cacioppo, A. David, A. Scialdone, I. Lorusso, G. Modorati, P. Corradini, V. Montefusco. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - (2018 Jul). [Epub ahead of print] [10.1080/10428194.2018.1480770]
Ocular disorders in multiple myeloma patients: cross-sectional study of prevalence and association with treatment
M. Pennisi;A. Mussetti;V. Cacioppo;A. David;P. Corradini;
2018
Abstract
Multiple myeloma (MM) therapy is evolving, and several new drugs are now available, extending patients’ life and exposure to different compounds and toxicities. We conducted a cross-sectional observational study enrolling 93 consecutive patients on active treatment for MM, aiming to assess their ocular complications. All the patients underwent a comprehensive ophthalmic evaluation. In our cohort, prevalence of low visual acuity was in line with similar age healthy population reported in registry studies. Interestingly, we recorded a higher prevalence of lens opacities (46%) and dry eye syndrome (53%). Nevertheless, we did not find any significant association between ocular disorders and anti-myeloma treatments, even steroid therapy. This observation suggests that other factors besides treatments, such as M-protein deposition in eye structures, may have a role in developing ocular toxicities. Since MM patients are elderly patients at higher risk of age-related eye disorders, we recommend periodic ophthalmic assessment in daily practice.File | Dimensione | Formato | |
---|---|---|---|
Ocular disorders in multiple myeloma patients cross sectional study of prevalence and association with treatment.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
782.59 kB
Formato
Adobe PDF
|
782.59 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.